Abstract
Forged in the early 1960s, the paradigm for pharmaceutical innovation has remained virtually unchanged for nearly 50 years. During a period when most other research-based industries have made frequent and often sweeping modifications to their R&D processes, the pharmaceutical sector continues to utilize a drug development process that is slow, inefficient, risky, and expensive. Few who work in or follow the activities of the pharmaceutical industry question whether change is coming. They know that the pharmaceutical sector, as currently structured, is unable to deliver enough new products to market to generate revenues sufficient to sustain its own growth. Nearly all major drug developers are critically examining current R&D practices and, in some cases, considering a radical overhaul of their R&D models. But key questions remain. What will the landscape for pharmaceutical innovation look like in the future? And, who will develop tomorrow’s medicines?
Keywords
Pharmaceutical industryRevenueClinical pharmacologyDrug developmentProcess (computing)Face (sociological concept)BusinessDrugPharmaceutical sciencesMarketingMedicinePharmacologyComputer scienceAccountingSociologySocial science
Affiliated Institutions
Related Publications
Quality Ladders in the Theory of Growth
We develop a model of repeated product improvements in a continuum of sectors. Each product follows a stochastic progression up a quality ladder. Progress is not uniform across ...
Diagnosing the decline of major pharmaceutical research laboratories: A prescription for drug companies
Abstract Despite dramatically increasing expenditures for in‐house pharmaceutical research and development (R&D) at major drug companies, few internally discovered, breakthr...
R&D management strategies: America versus Japan
This paper outlines some differences between the American and Japanese approaches to R&D management and suggests future trends. Data from a comparative study of U.S. and Japanes...
Absorptive Capacity: A New Perspective on Learning and Innovation
In this paper, we argue that the ability of a firm to recognize the value of new, external information, assimilate it, and apply it to commercial ends is critical to its innovat...
Natural Products for Drug Discovery in the 21st Century: Innovations for Novel Drug Discovery
The therapeutic properties of plants have been recognised since time immemorial. Many pathological conditions have been treated using plant-derived medicines. These medicines ar...
Publication Info
- Year
- 2010
- Type
- review
- Volume
- 87
- Issue
- 3
- Pages
- 356-361
- Citations
- 403
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
403
OpenAlex
Cite This
Kenneth I. Kaitin
(2010).
Deconstructing the Drug Development Process: The New Face of Innovation.
Clinical Pharmacology & Therapeutics
, 87
(3)
, 356-361.
https://doi.org/10.1038/clpt.2009.293
Identifiers
- DOI
- 10.1038/clpt.2009.293